Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 146

1.

PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.

Bittner VA, Giugliano RP, Brinton EA, Guyton JR.

J Clin Lipidol. 2018 Jul - Aug;12(4):835-843. doi: 10.1016/j.jacl.2018.06.013. Review.

PMID:
30055750
2.

From the editor: O Canada! A tariff-free zone for scientific exchange.

Guyton JR.

J Clin Lipidol. 2018 Jul - Aug;12(4):831-832. doi: 10.1016/j.jacl.2018.06.014. No abstract available.

PMID:
30055749
3.

Roundtable discussion: Dietary fats in prevention of atherosclerotic cardiovascular disease.

Severson T, Kris-Etherton PM, Robinson JG, Guyton JR.

J Clin Lipidol. 2018 May - Jun;12(3):574-582. doi: 10.1016/j.jacl.2018.05.006. Epub 2018 May 14. Review.

PMID:
29880281
4.

Old news and a new order.

Guyton JR.

J Clin Lipidol. 2018 May - Jun;12(3):571. doi: 10.1016/j.jacl.2018.05.005. No abstract available.

PMID:
29880280
5.

From the editor: Weighing the advantages of lipid conference and journal.

Guyton JR.

J Clin Lipidol. 2018 Mar - Apr;12(2):251-252. doi: 10.1016/j.jacl.2018.03.001. No abstract available.

PMID:
29606395
6.

Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.

Brinton EA, Ballantyne CM, Guyton JR, Philip S, Doyle RT Jr, Juliano RA, Mosca L.

J Womens Health (Larchmt). 2018 Mar 27. doi: 10.1089/jwh.2017.6757. [Epub ahead of print]

PMID:
29583081
7.

From the editor: A run of success in treating atherosclerotic vascular disease.

Guyton JR.

J Clin Lipidol. 2018 Jan - Feb;12(1):1-2. doi: 10.1016/j.jacl.2017.12.016. Epub 2017 Dec 29. No abstract available.

PMID:
29452916
8.

Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial.

Otvos JD, Guyton JR, Connelly MA, Akapame S, Bittner V, Kopecky SL, Lacy M, Marcovina SM, Muhlestein JB, Boden WE.

J Clin Lipidol. 2018 Mar - Apr;12(2):348-355.e2. doi: 10.1016/j.jacl.2018.01.002. Epub 2018 Jan 12.

9.

From the Editor.

Guyton JR.

J Clin Lipidol. 2017 Nov - Dec;11(6):1297. doi: 10.1016/j.jacl.2017.10.025. No abstract available.

PMID:
29157664
10.

Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry.

Amrock SM, Duell PB, Knickelbine T, Martin SS, O'Brien EC, Watson KE, Mitri J, Kindt I, Shrader P, Baum SJ, Hemphill LC, Ahmed CD, Andersen RL, Kullo IJ, McCann D, Larry JA, Murray MF, Fishberg R, Guyton JR, Wilemon K, Roe MT, Rader DJ, Ballantyne CM, Underberg JA, Thompson P, Duffy D, Linton MF, Shapiro MD, Moriarty PM, Knowles JW, Ahmad ZS.

Atherosclerosis. 2017 Dec;267:19-26. doi: 10.1016/j.atherosclerosis.2017.10.006. Epub 2017 Oct 6.

PMID:
29080546
11.

From the Editor.

Guyton JR.

J Clin Lipidol. 2017 Sep - Oct;11(5):1109. doi: 10.1016/j.jacl.2017.08.012. No abstract available.

PMID:
28943037
12.

Niacin and heart disease prevention: Engraving its tombstone is a mistake.

Superko HR, Zhao XQ, Hodis HN, Guyton JR.

J Clin Lipidol. 2017 Nov - Dec;11(6):1309-1317. doi: 10.1016/j.jacl.2017.08.005. Epub 2017 Aug 24. Review.

13.

Marine omega-3 fatty acids and cardiac death.

Guyton JR.

J Clin Lipidol. 2017 Sep - Oct;11(5):1124-1125. doi: 10.1016/j.jacl.2017.08.009. Epub 2017 Aug 23. No abstract available.

PMID:
28869141
14.

Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).

Mosca L, Ballantyne CM, Bays HE, Guyton JR, Philip S, Doyle RT Jr, Juliano RA.

Am J Cardiol. 2017 Feb 1;119(3):397-403. doi: 10.1016/j.amjcard.2016.10.027. Epub 2016 Nov 1.

15.

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.

Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M; ODYSSEY CHOICE II Investigators.

J Am Heart Assoc. 2016 Sep 13;5(9). pii: e003421. doi: 10.1161/JAHA.116.003421.

16.

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.

Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, Pordy R, Stroes E.

Cardiovasc Drugs Ther. 2016 Oct;30(5):473-483.

17.

Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.

Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH.

J Clin Lipidol. 2016 Jul-Aug;10(4):905-914. doi: 10.1016/j.jacl.2016.03.008. Epub 2016 Mar 23.

PMID:
27578122
18.

Statin intolerance in a referral lipid clinic.

Lakey WC, Greyshock NG, Kelley CE, Siddiqui MA, Ahmad U, Lokhnygina YV, Guyton JR.

J Clin Lipidol. 2016 Jul-Aug;10(4):870-879.e3. doi: 10.1016/j.jacl.2016.03.004. Epub 2016 Mar 17.

PMID:
27578118
19.

Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH.

Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE.

Am J Med. 2016 Jul;129(7):753.e13-22. doi: 10.1016/j.amjmed.2016.02.039. Epub 2016 Mar 29.

20.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.

Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators.

J Clin Lipidol. 2015 Nov-Dec;9(6):758-769. doi: 10.1016/j.jacl.2015.08.006. Epub 2015 Aug 29.

Supplemental Content

Loading ...
Support Center